We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
(+24%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$50.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$39.4M |
| 3 |
Intel
INTC
|
+$29.2M |
| 4 |
Qualcomm
QCOM
|
+$27.6M |
| 5 |
Danaher
DHR
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$49.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$41.6M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$26.5M |
| 4 |
Arrowhead Research
ARWR
|
+$24.9M |
| 5 |
Merck
MRK
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.73% |
| 2 | Technology | 19.55% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 9.32% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
McDonald's
MCD
$188B
| $17.4M | 0.19% |
88,237
-591
| -0.7% | -$117K |
|
127
Becton Dickinson
BDX
$43.1B
| $17.2M | 0.18% |
64,788
+2,777
| +4% | +$692K |
|
128
Southwest Airlines
LUV
$22.1B
| $16.9M | 0.18% |
312,415
-7,155
| -2% | -$397K |
|
129
Jones Lang LaSalle
JLL
$15.1B
| $16.5M | 0.18% |
94,647
+30,958
| +49% | +$4.87M |
|
130
Heron Therapeutics
HRTX
$86.3M
| $16.5M | 0.18% |
700,510
-306,090
| -30% | -$6.77M |
|
131
Mondelez International
MDLZ
$77.7B
| $16.4M | 0.18% |
296,908
+14,401
| +5% | +$770K |
|
132
HCA Healthcare
HCA
$84.8B
| $16.3M | 0.17% |
110,009
+10,700
| +11% | +$1.44M |
|
133
NetEase
NTES
$76.5B
| $16.2M | 0.17% |
264,625
+216,135
| +446% | +$12.7M |
|
134
Karyopharm Therapeutics
KPTI
$168M
| $16.2M | 0.17% |
56,356
-15,126
| -21% | -$3.28M |
|
|
AERI
135
DELISTED
Aerie Pharmaceuticals
AERI
| $16.2M | 0.17% |
669,800
-30,000
| -4% | -$621K |
|
136
Netflix
NFLX
$292B
| $16.1M | 0.17% |
497,850
-50,810
| -9% | -$1.51M |
|
137
Newmont
NEM
$98.2B
| $16M | 0.17% |
368,387
-135,897
| -27% | -$5.31M |
|
138
Morgan Stanley
MS
$337B
| $15.9M | 0.17% |
311,270
+43,812
| +16% | +$2.07M |
|
139
Elevance Health
ELV
$81.9B
| $15.9M | 0.17% |
52,681
-1,143
| -2% | -$315K |
|
140
Kinder Morgan
KMI
$73.1B
| $15.9M | 0.17% |
750,973
-12,114
| -2% | -$245K |
|
141
3M
MMM
$89B
| $15.8M | 0.17% |
107,279
-4,359
| -4% | -$611K |
|
142
Ionis Pharmaceuticals
IONS
$9.35B
| $15.8M | 0.17% |
261,700
-31,500
| -11% | -$1.88M |
|
143
Fortive
FTV
$19B
| $15.7M | 0.17% |
325,964
+20,252
| +7% | +$915K |
|
144
Ascendis Pharma A/S
ASND
$16.7B
| $15.6M | 0.17% |
112,000
+18,000
| +19% | +$2M |
|
145
New Oriental
EDU
$7.84B
| $15.3M | 0.16% |
126,600
+110,600
| +691% | +$13.2M |
|
146
Honeywell
HON
$77.1B
| $15.1M | 0.16% |
90,436
+47,209
| +109% | +$7.72M |
|
147
Eagle Materials
EXP
$6.6B
| $14.9M | 0.16% |
+164,547
| New | +$15.1M |
|
148
Cigna
CI
$76.6B
| $14.7M | 0.16% |
72,055
+2,168
| +3% | +$397K |
|
149
Capital One
COF
$124B
| $14.7M | 0.16% |
142,983
+25,536
| +22% | +$2.46M |
|
150
Consolidated Edison
ED
$41.6B
| $14.6M | 0.16% |
161,243
+49,884
| +45% | +$4.47M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2019 Portfolio in Review
As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.
- Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
- Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
- Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
- Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
- Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
- Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
- Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.
Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.